SLP Stock Overview
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide.
No risks detected for SLP from our risk checks.
Simulations Plus Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$65.10|
|52 Week High||US$67.59|
|52 Week Low||US$35.18|
|1 Month Change||15.96%|
|3 Month Change||44.35%|
|1 Year Change||44.89%|
|3 Year Change||74.30%|
|5 Year Change||350.52%|
|Change since IPO||4,634.55%|
Recent News & Updates
Simulations Plus goes ex-dividend tomorrow
Simulations Plus (NASDAQ:SLP) had declared $0.06/share quarterly dividend, in line with previous. Payable Aug. 1; for shareholders of record July 25; ex-div July 22. See SLP Dividend Scorecard, Yield Chart, & Dividend Growth.
Simulations Plus Q3 2022 Earnings Preview
Simulations Plus (NASDAQ:SLP) is scheduled to announce Q3 earnings results on Wednesday, July 6th, after market close. The consensus EPS Estimate is $0.17 (-5.6% Y/Y) and the consensus Revenue Estimate is $14.33M (+12.1% Y/Y). Over the last 1 year, SLP has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. Revenue estimates have seen 0 upward revisions and 1 downward.
|SLP||US Healthcare Services||US Market|
Return vs Industry: SLP exceeded the US Healthcare Services industry which returned -44.1% over the past year.
Return vs Market: SLP exceeded the US Market which returned -10.2% over the past year.
|SLP Average Weekly Movement||6.5%|
|Healthcare Services Industry Average Movement||11.7%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: SLP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SLP's weekly volatility (7%) has been stable over the past year.
About the Company
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Simulations Plus Fundamentals Summary
|SLP fundamental statistics|
Is SLP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SLP income statement (TTM)|
|Cost of Revenue||US$10.93m|
Last Reported Earnings
May 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.58|
|Net Profit Margin||22.74%|
How did SLP perform over the long term?See historical performance and comparison
0.4%Current Dividend Yield
Is SLP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SLP?
Other financial metrics that can be useful for relative valuation.
|What is SLP's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does SLP's PE Ratio compare to its peers?
|SLP PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
MDRX Allscripts Healthcare Solutions
NUTX Nutex Health
SLP Simulations Plus
Price-To-Earnings vs Peers: SLP is expensive based on its Price-To-Earnings Ratio (111.4x) compared to the peer average (37.8x).
Price to Earnings Ratio vs Industry
How does SLP's PE Ratio compare vs other companies in the Global Healthcare Services Industry?
Price-To-Earnings vs Industry: SLP is expensive based on its Price-To-Earnings Ratio (111.4x) compared to the US Healthcare Services industry average (37.3x)
Price to Earnings Ratio vs Fair Ratio
What is SLP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||111.4x|
|Fair PE Ratio||31.6x|
Price-To-Earnings vs Fair Ratio: SLP is expensive based on its Price-To-Earnings Ratio (111.4x) compared to the estimated Fair Price-To-Earnings Ratio (31.6x).
Share Price vs Fair Value
What is the Fair Price of SLP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SLP ($65.1) is trading above our estimate of fair value ($37.72)
Significantly Below Fair Value: SLP is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
How is Simulations Plus forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLP's forecast earnings growth (20.6% per year) is above the savings rate (1.9%).
Earnings vs Market: SLP's earnings (20.6% per year) are forecast to grow faster than the US market (14.5% per year).
High Growth Earnings: SLP's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SLP's revenue (18.1% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: SLP's revenue (18.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SLP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Simulations Plus performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SLP has high quality earnings.
Growing Profit Margin: SLP's current net profit margins (22.7%) are lower than last year (25.3%).
Past Earnings Growth Analysis
Earnings Trend: SLP's earnings have grown by 11.5% per year over the past 5 years.
Accelerating Growth: SLP's earnings growth over the past year (1.4%) is below its 5-year average (11.5% per year).
Earnings vs Industry: SLP earnings growth over the past year (1.4%) underperformed the Healthcare Services industry 2.8%.
Return on Equity
High ROE: SLP's Return on Equity (6.7%) is considered low.
Discover strong past performing companies
How is Simulations Plus's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: SLP's short term assets ($144.9M) exceed its short term liabilities ($5.9M).
Long Term Liabilities: SLP's short term assets ($144.9M) exceed its long term liabilities ($2.7M).
Debt to Equity History and Analysis
Debt Level: SLP is debt free.
Reducing Debt: SLP has not had any debt for past 5 years.
Debt Coverage: SLP has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: SLP has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Simulations Plus's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SLP's dividend (0.37%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.47%).
High Dividend: SLP's dividend (0.37%) is low compared to the top 25% of dividend payers in the US market (3.95%).
Stability and Growth of Payments
Stable Dividend: SLP is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: SLP is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: SLP is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: SLP is not paying a notable dividend for the US market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Shawn O'Connor (62 yo)
Mr. Shawn M. O'Connor has been Chief Executive Officer of Simulations Plus, Inc. since June 26, 2018. Mr. O'Connor served as Chief Executive Officer of Entelos, Inc. since July, 2011. Mr. O'Connor is a sea...
CEO Compensation Analysis
Compensation vs Market: Shawn's total compensation ($USD1.07M) is below average for companies of similar size in the US market ($USD5.40M).
Compensation vs Earnings: Shawn's compensation has increased by more than 20% in the past year.
Experienced Management: SLP's management team is considered experienced (2.4 years average tenure).
Experienced Board: SLP's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Simulations Plus, Inc.'s employee growth, exchange listings and data sources
- Name: Simulations Plus, Inc.
- Ticker: SLP
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: US$1.299b
- Shares outstanding: 20.24m
- Website: https://www.simulations-plus.com
Number of Employees
- Simulations Plus, Inc.
- 42505 Tenth Street West
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/15 00:00|
|End of Day Share Price||2022/08/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.